Compare Stocks: KURA, RLAY, LEGN, and VCYT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$10.81 +1.9%	$11.22	$7.36 ▼ $13.90	$943.88M	0.44	1.72 million shs	1.89 million shs
LEGN Legend Biotech	$18.82 +1.1%	$20.06	$16.24 ▼ $37.50	$3.65B	0.4	2.09 million shs	1.97 million shs
RLAY Relay Therapeutics	$18.36 +3.8%	$19.13	$5.07 ▼ $21.27	$3.88B	1.69	3.35 million shs	3.52 million shs
VCYT Veracyte	$46.08 +1.9%	$45.39	$29.45 ▼ $60.91	$3.64B	1.93	1.37 million shs	1.57 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	+1.89%	-7.84%	-14.61%	+0.28%	+20.51%
LEGN Legend Biotech	+1.07%	+0.97%	-5.33%	-37.04%	-42.71%
RLAY Relay Therapeutics	+3.79%	-5.12%	-2.18%	+3.38%	+253.76%
VCYT Veracyte	+1.88%	+6.27%	+6.32%	-23.01%	+37.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$10.81 +1.9%	$11.22	$7.36 ▼ $13.90	$943.88M	0.44	1.72 million shs	1.89 million shs
LEGN Legend Biotech	$18.82 +1.1%	$20.06	$16.24 ▼ $37.50	$3.65B	0.4	2.09 million shs	1.97 million shs
RLAY Relay Therapeutics	$18.36 +3.8%	$19.13	$5.07 ▼ $21.27	$3.88B	1.69	3.35 million shs	3.52 million shs
VCYT Veracyte	$46.08 +1.9%	$45.39	$29.45 ▼ $60.91	$3.64B	1.93	1.37 million shs	1.57 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	+1.89%	-7.84%	-14.61%	+0.28%	+20.51%
LEGN Legend Biotech	+1.07%	+0.97%	-5.33%	-37.04%	-42.71%
RLAY Relay Therapeutics	+3.79%	-5.12%	-2.18%	+3.38%	+253.76%
VCYT Veracyte	+1.88%	+6.27%	+6.32%	-23.01%	+37.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KURA Kura Oncology	2.75	Moderate Buy	$25.40	134.97% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$55.79	196.42% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	41.16% Upside
VCYT Veracyte	2.82	Moderate Buy	$55.78	21.05% Upside

Current Analyst Ratings Breakdown

Latest KURA, RLAY, LEGN, and VCYT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/16/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/15/2026	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$78.00 ➝ $74.00
9/9/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KURA Kura Oncology	$77.23M	12.45	N/A	N/A	$2.00 per share	5.41
LEGN Legend Biotech	$1.27B	2.87	N/A	N/A	$5.43 per share	3.47
RLAY Relay Therapeutics	$10.35M	388.74	N/A	N/A	$3.27 per share	5.61
VCYT Veracyte	$561.90M	6.59	$1.52 per share	30.36	$16.57 per share	2.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	16.09	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	32.68	29.92	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest KURA, RLAY, LEGN, and VCYT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KURA Kura Oncology	0.12	4.73	4.71
LEGN Legend Biotech	N/A	3.04	2.94
RLAY Relay Therapeutics	N/A	18.27	18.27
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KURA Kura Oncology	N/A
LEGN Legend Biotech	70.89%
RLAY Relay Therapeutics	96.98%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
KURA Kura Oncology	7.60%
LEGN Legend Biotech	0.02%
RLAY Relay Therapeutics	5.04%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable

KURA, RLAY, LEGN, and VCYT Headlines

Recent News About These Companies

Veracyte, Inc. Reports NRG/RTOG 0815 Analysis Shows Decipher Prostate Genomic Classifier Predicts Benefit From Adding Short-Term Androgen Deprivation Therapy To Dose-Escalated ...

September 29 at 7:41 PM | marketscreener.comM

Veracyte's Decipher Test Predicts Hormone Therapy Benefit In Phase 3 Prostate Cancer Analysis

September 29 at 2:40 PM | rttnews.com

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 29 at 9:39 AM | markets.businessinsider.com

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 29 at 8:00 AM | globenewswire.com

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

September 25, 2026 | globenewswire.com

Veracyte (NASDAQ:VCYT) Stock Falls 5.7% - Time to Sell?

September 25, 2026 | marketbeat.com

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

September 25, 2026 | zacks.com

Veracyte (NASDAQ:VCYT) Shares Up 6.5% - Still a Buy?

September 24, 2026 | marketbeat.com

John Leite Sells 4,015 Shares of Veracyte (NASDAQ:VCYT) Stock

September 22, 2026 | marketbeat.com

Veracyte Acquires Convergent Genomics For Up To $180 Million To Add Urinary Tumor DNA Bladder Cancer Platform

September 21, 2026 | pulse2.comP

Bank of America Corp DE Invests $64.74 Million in Veracyte, Inc. $VCYT

September 20, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

September 19, 2026 | theglobeandmail.com

Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT

September 19, 2026 | marketbeat.com

Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT

September 17, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Director Jens Holstein Sells 5,000 Shares

September 16, 2026 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16, 2026 | marketbeat.com

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

September 15, 2026 | marketscreener.comM

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Veracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 15, 2026 | finanznachrichten.de

Veracyte Buys Convergent Genomics

September 14, 2026 | finance.yahoo.com

Veracyte Acquires Convergent Genomics For $150 Mln In Cash

September 14, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, RLAY, LEGN, and VCYT Company Descriptions

Kura Oncology NASDAQ:KURA

$10.81 +0.20 (+1.89%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$10.89 +0.08 (+0.72%)

As of 07:52 AM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Legend Biotech NASDAQ:LEGN

$18.82 +0.20 (+1.07%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$19.07 +0.25 (+1.33%)

As of 07:28 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Relay Therapeutics NASDAQ:RLAY

$18.36 +0.67 (+3.79%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$18.25 -0.11 (-0.60%)

As of 07:41 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Veracyte NASDAQ:VCYT

$46.08 +0.85 (+1.88%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$46.40 +0.32 (+0.69%)

As of 07:17 AM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KURA, RLAY, LEGN, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KURA, RLAY, LEGN, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KURA, RLAY, LEGN, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, RLAY, LEGN, and VCYT Company Descriptions

Kura Oncology NASDAQ:KURA

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KURA, RLAY, LEGN, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KURA, RLAY, LEGN, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KURA, RLAY, LEGN, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, RLAY, LEGN, and VCYT Company Descriptions

Kura Oncology NASDAQ:KURA

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools